Comparative renoprotective effectiveness of allopurinol and febuxostat among hyperuricaemic patients with preserved kidney function
Modern Rheumatology · 2025
DOI: 10.1093/mr/roae115 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Modern Rheumatology, 2025. Verfasst von Atsushi Takayama und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacoepidemiology, Kyoto University Graduate School of Medicine and Public Health, Kyoto, Japan. Hauptthemen laut MEDLINE: Febuxostat, Allopurinol, Hyperuricemia, Gout Suppressants. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 53 Literaturangaben.
Abstract (Originalsprache)
Objectives
Early initiation of xanthine oxidase inhibitors may benefit patients with preserved kidney function. However, a direct comparison between the impact of allopurinol and that of febuxostat on long-term kidney function among this population is lacking.
Methods
We conducted a retrospective cohort study with a new-user, active-comparator design among patients with estimated glomerular filtration rate (eGFR) within the reference range and no proteinuria. The primary outcome was a composite incidence of significant eGFR decline (≥40% decline from baseline) and all-cause death at 5 years. Adjusted hazard ratios were estimated using Cox’s proportional hazard models with inverse probability of treatment and censoring weighting.
Results
We analysed 1142 patients (287 with allopurinol and 855 with febuxostat). The adjusted hazard ratios (95% confidence intervals) for allopurinol initiators compared to febuxostat initiators for the composite outcome at 5 years were 0.84 (0.74–0.95). The cause-specific adjusted hazard ratios for allopurinol initiators relative to febuxostat initiators were 0.82 (0.70–0.94) for significant eGFR decline >5 years and 1.08 (0.91–1.24) for all-cause death >5 years.
Conclusions
Allopurinol initiators preserved kidney function better than febuxostat >5 years. Clinicians should exercise caution not only when prescribing but also when selecting xanthine oxidase inhibitors, even for patients with preserved kidney function.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacoepidemiology, Kyoto University Graduate School of Medicine and Public Health, Kyoto, Japan.
- Department of Digital Health and Epidemiology, Graduate School of Medicine and Public Health, Kyoto University, Kyoto, Japan.
- Graduate School of Public Health, Shizuoka Graduate University of Public Health, Shizuoka, Japan.
ORCID-Profile: Atsushi Takayama
Zitieren
APA
Takayama, A., Fukasawa, T., Takeuchi, M., & Kawakami, K. (2025). Comparative renoprotective effectiveness of allopurinol and febuxostat among hyperuricaemic patients with preserved kidney function. Modern Rheumatology. https://doi.org/10.1093/mr/roae115
Vancouver
Takayama A, Fukasawa T, Takeuchi M, Kawakami K. Comparative renoprotective effectiveness of allopurinol and febuxostat among hyperuricaemic patients with preserved kidney function. Modern Rheumatology. 2025. doi:10.1093/mr/roae115
BibTeX
@article{Takayama2025,
author = {Takayama, Atsushi and Fukasawa, Toshiki and Takeuchi, Masato and Kawakami, Koji},
title = {Comparative renoprotective effectiveness of allopurinol and febuxostat among hyperuricaemic patients with preserved kidney function},
journal = {Modern Rheumatology},
year = {2025},
doi = {10.1093/mr/roae115}
}
EUVIMED